Skip to main content
Skip to content
Case File
efta-efta01783325DOJ Data Set 10Correspondence

EFTA Document EFTA01783325

Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01783325
Pages
0
Persons
0
Integrity
Loading PDF viewer...

Summary

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Richard Kahn Sent: Thursday, September 15, 2016 3:23 PM To: jeffrey E. Subject: Fwd: REGN trade idea Richard Kahn HBRK Associates Inc. 575 Lexington =venue 4th Floor New York, NY 10022 tel fax cell Begin forwarded message: From: =/b>"Ens, Amanda" Subject: =/b>REGN trade =dea Date: =/b>September 15, 2016 at 9:28:55 =M EDT To: =/b>' Cc: "Jaye, Matthew W" < 1 Rich, Not sure if you still =ave a lot of biotech exposure but Matt and I wanted to highlight =egeneron Pharmaceuticals. REGN (Buy, $397.56 last, 12m PO =526) Sell =an 350 put / buy Jan 420-480 call spread -> paying $3 (less than 1% =f spot ref 397.56). (we need to trade this in note format) EFTA_R1_00103857 EFTA01783325 Trading thinks we are =ow at a good entry point for REGN longs following the BAML FIC confer in =ondon and an investor dinner with the company. Few thoughts =elow. 3 key =ear term catalysts that represent significant upside: 1. We see an =njunction against key cholesterol drug Praluent as highly unlikely. =iming in uncertain, but could come in the next few months based on =istorical precedent. A positive ruling or a settlement with AMGN =epresents 10%+ upside. 2. Management felt very confident that the =nterim look for the LDL outcomes study will show a meaningful reduction =n cardiovascular events (expected by YE) 3. Management expects a strong launch for Dupilumab =n atopic dermatitis, and proactive conversations with the payers have =een initiated, facilitating their expectation of reimbursement. On the vol front, =mplieds are relatively low at 35% compared to the 33-49 vol range seen =ver the past year. Source: =loomberg Stock =epeatedly sees strong support in the $350 range Source: Bloomberg Matthew Jaye Equity Derivative Sales Bank of America Merrill Lynch Merrill Lynch, Pierce, Fenner & Smith =ncorporated One Bryant Park, New York, NY 10036 2 EFTA_R1_00103858 EFTA01783326 Amanda Ens Director Bank of America Merrill =ynch Merrill Lynch, =ierce, Fenner & Smith Incorporated One Bryant Park, 5th Floor, New York, NY 10036 The power =f global connections" This message, and any attachments, is for the intended =ecipient(s) only, may contain information that is privileged, =onfidential and/or proprietary and subject to important terms and =onditions available at http://www.bankofamerica.com/emaildisclaimer. If you =re not the intended recipient, please delete this message. 3 EFTA_R1_001 03859 EFTA01783327

Technical Artifacts (1)

View in Artifacts Browser

Email addresses, URLs, phone numbers, and other technical indicators extracted from this document.

URLhttp://www.bankofamerica.com/emaildisclaimer

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.